Skip to content
Grantfox

Cascade funding · EP PerMed

Cell and Gene Therapy for Personalised Medicine (CGT4PM2027)

Read by Grantfox from the official page on 21 Nov 2026. Verify every detail there before applying: official call page.

What it funds

With this JTC, EP PerMed will fund research projects in human health on Cell and Gene Therapies (CGT) for PM approaches. Proposals must focus on the development and validation of an innovative and novel CGT for PM. At least one of the following approaches must be employed: • Somatic cell therapeutics; • Gene therapeutics; • Combined cell- and gene therapeutics; • Novel biological products. For the entire scope, please consult the Call Text: https://www.eppermed.eu/funding-projects/calls/jtc2027/. Applicants should contact their corresponding regional/national representative to enquire about eligibility with their respective funding organisations prior to submitting an application (see regional/national contact details, Annex I of the call text). For additional information, please contact the JCS ([email protected]). Adherence to the regional/national funding regulations in the “Guidelines for Applicants” document is mandatory (www.eppermed.eu).

Conditions and eligibility

All information and documents concerning the EP PerMed Joint Transnational Call (JTC) 2027, including the call text outlining the aims and scope of the call, the Guidelines for Applicants document, the pre-proposal form, etc. can be found here: https://www.eppermed.eu/funding-projects/calls/jtc2027/. Electronic submission system: https://ptoutline.eu/app/eppermed2027. Deadline to submit pre-proposals: 20 January 2027 (14:00, CET) Deadline to submit full proposals: 25 May 2027 (14:00, CEST)